Genelux (GNLX) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Genelux (GNLX) has outperformed Inovio Pharmaceuticals (INO) over the past year, losing 54.9% versus a loss of 56.6%. Inovio Pharmaceuticals is the larger company by market cap ($118.9 million vs $115.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | INO |
|---|---|---|
| Share price | $2.56 | $1.15 |
| Market cap | $115.83M | $118.91M |
| 1-day change | +2.40% | +5.50% |
| YTD return | -41.28% | -33.91% |
| 1-year return | -54.85% | -56.60% |
| 5-year return | — | -98.63% |
| EPS (TTM) | $-0.86 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $2.72 |
| 52-week low | $2.29 | $0.56 |
| Distance from 52-week high | -70.01% | -57.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +635.55% | +175.65% |
| Average volume | 276.60K | 3.90M |
| Shares outstanding | 45.25M | 103.40M |
| Employees | 25 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
GNLX vs INO FAQ
Which is bigger, Genelux or Inovio Pharmaceuticals?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $118.91M compared with $115.83M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or INO?
GNLX returned -54.85% over the past 12 months, compared with -56.60% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.